Literature DB >> 6538316

Idiopathic hyperCKemia.

N Sunohara, A Takagi, I Nonaka, H Sugita, E Satoyoshi.   

Abstract

In three adult men, serum creatine kinase activity was constantly raised for at least 4 years. They had been normal in other neuromuscular functions and did not have any established disease. Quantitative morphologic and pharmacologic studies were performed on biopsied muscle. The biceps brachii of patient 1 contained 0.3% necrotic fibers. In patient 2, only slight variation of muscle fiber diameter was noted. Muscle of patient 3 contained a few small angular fibers, and 11% of fibers exhibited internal nuclei. Sensitivity to caffeine in vitro was increased in patients 2 and 3, as seen in survivors of malignant hyperthermia; patients in hyperCKemia may be susceptible to malignant hyperthermia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538316     DOI: 10.1212/wnl.34.4.544

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

Review 1.  Investigation of muscle disease.

Authors:  F L Mastaglia; N G Laing
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

Review 2.  McLeod syndrome: a distinct form of neuroacanthocytosis. Report of two cases and literature review with emphasis on neuromuscular manifestations.

Authors:  T N Witt; A Danek; M Reiter; M U Heim; J Dirschinger; E G Olsen
Journal:  J Neurol       Date:  1992-07       Impact factor: 4.849

3.  Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects.

Authors:  Elisabetta D'Adda; Monica Sciacco; Maria Elisa Fruguglietti; Veronica Crugnola; Valeria Lucchini; Filippo Martinelli-Boneschi; Chiara Zecca; Costanza Lamperti; Giacomo Pietro Comi; Nereo Bresolin; Maurizio Moggio; Alessandro Prelle
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

4.  Malignant hyperthermia.

Authors:  Dong-Chan Kim
Journal:  Korean J Anesthesiol       Date:  2012-11-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.